Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Plasma protein binding displacement interactions--why are they still regarded as clinically important?

Literature DB >> 8186058

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

P E Rolan¹.

Abstract

Mesh：

Substances：
Blood Proteins

Year: 1994 PMID： 8186058 PMCID： PMC1364588 DOI： 10.1111/j.1365-2125.1994.tb04251.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

28 in total

Review 1. Binding of drugs to serum albumin (first of two parts).

Authors: J Koch-Weser; E M Sellers
Journal: N Engl J Med Date: 1976-02-05 Impact factor: 91.245

2. Commentary: a physiological approach to hepatic drug clearance.

Authors: G R Wilkinson; D G Shand
Journal: Clin Pharmacol Ther Date: 1975-10 Impact factor: 6.875

3. Effect of phenylbutazone on the binding of vitamin K antagonists to albumin.

Authors: J P Tillement; R Zini; C Mattei; E Singlas
Journal: Eur J Clin Pharmacol Date: 1973-06 Impact factor: 2.953

4. The effect of organic acids on renal clearance of methotrexate in man.

Authors: D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal: Clin Pharmacol Ther Date: 1969 Nov-Dec Impact factor: 6.875

5. Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate.

Authors: E M Sellers; J Koch-Weser
Journal: N Engl J Med Date: 1970-10-15 Impact factor: 91.245

6. Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs.

Authors: E M Sellers; J Koch-Weser
Journal: Ann N Y Acad Sci Date: 1971-07-06 Impact factor: 5.691

7. Effect of plasma protein and tissue binding on the biologic half-life of drugs.

Authors: M Gibaldi; G Levy; P J McNamara
Journal: Clin Pharmacol Ther Date: 1978-07 Impact factor: 6.875

8. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.

Authors: S M Pond; D J Birkett; D N Wade
Journal: Clin Pharmacol Ther Date: 1977-11 Impact factor: 6.875

9. Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction.

Authors: T D Bjornsson; P J Meffin; S Swezey; T F Blaschke
Journal: J Pharmacol Exp Ther Date: 1979-09 Impact factor: 4.030

Review 10. Drug interactions with oral sulphonylurea hypoglycaemic drugs.

Authors: J M Hansen; L K Christensen
Journal: Drugs Date: 1977-01 Impact factor: 9.546

46 in total

1. In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.

Authors: B M Sadler; C Gillotin; Y Lou; D S Stein
Journal: Antimicrob Agents Chemother Date: 2001-03 Impact factor: 5.191

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

Review 1. Binding of drugs to serum albumin (first of two parts).

2. Commentary: a physiological approach to hepatic drug clearance.

3. Effect of phenylbutazone on the binding of vitamin K antagonists to albumin.

4. The effect of organic acids on renal clearance of methotrexate in man.

5. Potentiation of warfarin-induced hypoprothrombinemia by chloral hydrate.

6. Kinetics and clinical importance of displacement of warfarin from albumin by acidic drugs.

7. Effect of plasma protein and tissue binding on the biologic half-life of drugs.

8. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.

9. Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction.

Review 10. Drug interactions with oral sulphonylurea hypoglycaemic drugs.

1. In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.

Review 2. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

3. Lack of interaction between meloxicam and warfarin in healthy volunteers.

Review 4. What is the true clinical significance of plasma protein binding displacement interactions?

5. A probable clinically significant interaction between warfarin and cloxacillin: three case reports.

Review 6. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.

Review 7. Clinically significant interactions with drugs used in the treatment of tuberculosis.

Review 8. Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations.

9. The clinical relevance of plasma protein binding changes.

10. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin.